EirGenix (6589) - Total Liabilities
Based on the latest financial reports, EirGenix (6589) has total liabilities worth NT$1.94 Billion TWD (≈ $61.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EirGenix - Total Liabilities Trend (2017–2024)
This chart illustrates how EirGenix's total liabilities have evolved over time, based on quarterly financial data. See EirGenix short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
EirGenix Competitors by Total Liabilities
The table below lists competitors of EirGenix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Community Bancshares Inc
NASDAQ:FCBC
|
USA | $2.68 Billion |
|
Beijing Vastdata Technology Co Ltd
SHG:603138
|
China | CN¥249.59 Million |
|
Hovnanian Enterprises Inc
NYSE:HOV
|
USA | $2.00 Billion |
|
Shanghai Jiaoda Onlly Co Ltd
SHG:600530
|
China | CN¥362.45 Million |
|
SENORES PHARMACEUTICALS L
NSE:SENORES
|
India | Rs4.54 Billion |
|
APG SGA SA
SW:APGN
|
Switzerland | CHF93.01 Million |
|
Catapult Group International Ltd
AU:CAT
|
Australia | AU$109.22 Million |
|
Sichuan Discovery Dream Science & Technology Co.Ltd
SHE:301213
|
China | CN¥164.53 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down EirGenix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6589 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EirGenix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EirGenix (2017–2024)
The table below shows the annual total liabilities of EirGenix from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.62 Billion ≈ $50.98 Million |
+41.31% |
| 2023-12-31 | NT$1.15 Billion ≈ $36.08 Million |
-1.65% |
| 2022-12-31 | NT$1.16 Billion ≈ $36.68 Million |
+15.03% |
| 2021-12-31 | NT$1.01 Billion ≈ $31.89 Million |
-47.55% |
| 2020-12-31 | NT$1.93 Billion ≈ $60.79 Million |
+1558.06% |
| 2019-12-31 | NT$116.38 Million ≈ $3.67 Million |
-86.89% |
| 2018-12-31 | NT$887.57 Million ≈ $27.96 Million |
+61.21% |
| 2017-12-31 | NT$550.56 Million ≈ $17.35 Million |
-- |
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more